Showcasing KRas Degrader-Antibody Conjugates as a Therapeutic Approach for Treating KRas Driven Colorectal Cancer
- Exploring how KRas degraders offer more complete KRas inhibition compared to small molecule inhibitors.
- Showing how KRas degrader-Certuximab conjugate has unique advantages in treating KRas driven colorectal cancer
- Highlighting Polymed’s KRas degrader and degrader-antibody conjugates demonstrated preclinical proof-of-concept